Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 Jan;71(1):40–47. doi: 10.1038/bjc.1995.9

Reduced topoisomerase II activity in multidrug-resistant human non-small cell lung cancer cell lines.

E W Eijdems 1, M de Haas 1, A J Timmerman 1, G P Van der Schans 1, E Kamst 1, J de Nooij 1, G C Astaldi Ricotti 1, P Borst 1, F Baas 1
PMCID: PMC2033439  PMID: 7819046

Abstract

Multidrug-resistant (MDR) cell lines often have a compound phenotype, combining reduced drug accumulation with a decrease in topoisomerase II. We have analysed alterations in topoisomerase II in MDR derivatives of the human lung cancer cell line SW-1573. Selection with doxorubicin frequently resulted in reduced topo II alpha mRNA and protein levels, whereas clones selected with vincristine showed normal levels of topo II alpha. No alterations of topo II beta levels were detected. To determine the contribution of topo II alterations to drug resistance, topo II activity was analysed by the determination of DNA breaks induced by the topo II-inhibiting drug 4'-(9-acridinylamino)methane-sulphon-m-anisidide (m-AMSA) in living cells, as m-AMSA is not affected by the drug efflux mechanism in the SW-1573 cells. The number of m-AMSA-induced DNA breaks correlated well (r = 0.96) with in vitro m-AMSA sensitivity. Drug sensitivity, however, did not always correlate with reduced topo II mRNA or protein levels. In one of the five doxorubicin-selected clones m-AMSA resistance and a reduction in m-AMSA-induced DNA breaks were found in the absence of reduced topo II protein levels. Therefore, we assume that post-translational modifications of topo II also contribute to drug resistance in SW-1573 cells. These results suggest that methods that detect quantitative as well as qualitative alterations of topo II should be used to predict the responsiveness of tumours to cytotoxic agents. The assay we used, which measures DNA breaks as an end point of topo II activity, could be a good candidate.

Full text

PDF
41

Images in this article

43Figure 1
on p.43
43Figure 2
on p.43
45Figure 4
on p.45

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baas F., Jongsma A. P., Broxterman H. J., Arceci R. J., Housman D., Scheffer G. L., Riethorst A., van Groenigen M., Nieuwint A. W., Joenje H. Non-P-glycoprotein mediated mechanism for multidrug resistance precedes P-glycoprotein expression during in vitro selection for doxorubicin resistance in a human lung cancer cell line. Cancer Res. 1990 Sep 1;50(17):5392–5398. [PubMed] [Google Scholar]
  2. Binaschi M., Giaccone G., Gazdar A. F., De Isabella P., Ricotti G. C., Capranico G., Zunino F. Characterization of a topoisomerase II gene rearrangement in a human small-cell lung cancer cell line. J Natl Cancer Inst. 1992 Nov 18;84(22):1710–1716. doi: 10.1093/jnci/84.22.1710. [DOI] [PubMed] [Google Scholar]
  3. Boege F., Kjeldsen E., Gieseler F., Alsner J., Biersack H. A drug-resistant variant of topoisomerase II alpha in human HL-60 cells exhibits alterations in catalytic pH optimum, DNA binding and sub-nuclear distribution. Eur J Biochem. 1993 Dec 1;218(2):575–584. doi: 10.1111/j.1432-1033.1993.tb18411.x. [DOI] [PubMed] [Google Scholar]
  4. Broxterman H. J., Pinedo H. M., Kuiper C. M., van der Hoeven J. J., de Lange P., Quak J. J., Scheper R. J., Keizer H. G., Schuurhuis G. J., Lankelma J. Immunohistochemical detection of P-glycoprotein in human tumor cells with a low degree of drug resistance. Int J Cancer. 1989 Feb 15;43(2):340–343. doi: 10.1002/ijc.2910430229. [DOI] [PubMed] [Google Scholar]
  5. Bugg B. Y., Danks M. K., Beck W. T., Suttle D. P. Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide. Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7654–7658. doi: 10.1073/pnas.88.17.7654. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Chen A. Y., Liu L. F. DNA topoisomerases: essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol. 1994;34:191–218. doi: 10.1146/annurev.pa.34.040194.001203. [DOI] [PubMed] [Google Scholar]
  7. Chu G., Vollrath D., Davis R. W. Separation of large DNA molecules by contour-clamped homogeneous electric fields. Science. 1986 Dec 19;234(4783):1582–1585. doi: 10.1126/science.3538420. [DOI] [PubMed] [Google Scholar]
  8. Cole S. P., Chanda E. R., Dicke F. P., Gerlach J. H., Mirski S. E. Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II. Cancer Res. 1991 Jul 1;51(13):3345–3352. [PubMed] [Google Scholar]
  9. Coutts J., Plumb J. A., Brown R., Keith W. N. Expression of topoisomerase II alpha and beta in an adenocarcinoma cell line carrying amplified topoisomerase II alpha and retinoic acid receptor alpha genes. Br J Cancer. 1993 Oct;68(4):793–800. doi: 10.1038/bjc.1993.430. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. DiNardo S., Voelkel K., Sternglanz R. DNA topoisomerase II mutant of Saccharomyces cerevisiae: topoisomerase II is required for segregation of daughter molecules at the termination of DNA replication. Proc Natl Acad Sci U S A. 1984 May;81(9):2616–2620. doi: 10.1073/pnas.81.9.2616. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Drake F. H., Hofmann G. A., Bartus H. F., Mattern M. R., Crooke S. T., Mirabelli C. K. Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry. 1989 Oct 3;28(20):8154–8160. doi: 10.1021/bi00446a029. [DOI] [PubMed] [Google Scholar]
  12. Earnshaw W. C., Halligan B., Cooke C. A., Heck M. M., Liu L. F. Topoisomerase II is a structural component of mitotic chromosome scaffolds. J Cell Biol. 1985 May;100(5):1706–1715. doi: 10.1083/jcb.100.5.1706. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Eder J. P., Jr, Chan V. T., Niemierko E., Teicher B. A., Schnipper L. E. Conditional expression of wild-type topoisomerase II complements a mutant enzyme in mammalian cells. J Biol Chem. 1993 Jul 5;268(19):13844–13849. [PubMed] [Google Scholar]
  14. Eijdems E. W., Borst P., Jongsma A. P., de Jong S., de Vries E. G., van Groenigen M., Versantvoort C. H., Nieuwint A. W., Baas F. Genetic transfer of non-P-glycoprotein-mediated multidrug resistance (MDR) in somatic cell fusion: dissection of a compound MDR phenotype. Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3498–3502. doi: 10.1073/pnas.89.8.3498. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Enoch T., Zinn K., Maniatis T. Activation of the human beta-interferon gene requires an interferon-inducible factor. Mol Cell Biol. 1986 Mar;6(3):801–810. doi: 10.1128/mcb.6.3.801. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Feldhoff P. W., Mirski S. E., Cole S. P., Sullivan D. M. Altered subcellular distribution of topoisomerase II alpha in a drug-resistant human small cell lung cancer cell line. Cancer Res. 1994 Feb 1;54(3):756–762. [PubMed] [Google Scholar]
  17. Ferguson P. J., Fisher M. H., Stephenson J., Li D. H., Zhou B. S., Cheng Y. C. Combined modalities of resistance in etoposide-resistant human KB cell lines. Cancer Res. 1988 Nov 1;48(21):5956–5964. [PubMed] [Google Scholar]
  18. Fernandes D. J., Danks M. K., Beck W. T. Decreased nuclear matrix DNA topoisomerase II in human leukemia cells resistant to VM-26 and m-AMSA. Biochemistry. 1990 May 1;29(17):4235–4241. doi: 10.1021/bi00469a028. [DOI] [PubMed] [Google Scholar]
  19. Friche E., Danks M. K., Schmidt C. A., Beck W. T. Decreased DNA topoisomerase II in daunorubicin-resistant Ehrlich ascites tumor cells. Cancer Res. 1991 Aug 15;51(16):4213–4218. [PubMed] [Google Scholar]
  20. Ganapathi R., Zwelling L., Constantinou A., Ford J., Grabowski D. Altered phosphorylation, biosynthesis and degradation of the 170 kDa isoform of topoisomerase II in amsacrine-resistant human leukemia cells. Biochem Biophys Res Commun. 1993 May 14;192(3):1274–1280. doi: 10.1006/bbrc.1993.1554. [DOI] [PubMed] [Google Scholar]
  21. Glisson B., Gupta R., Smallwood-Kentro S., Ross W. Characterization of acquired epipodophyllotoxin resistance in a Chinese hamster ovary cell line: loss of drug-stimulated DNA cleavage activity. Cancer Res. 1986 Apr;46(4 Pt 2):1934–1938. [PubMed] [Google Scholar]
  22. Grant C. E., Valdimarsson G., Hipfner D. R., Almquist K. C., Cole S. P., Deeley R. G. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res. 1994 Jan 15;54(2):357–361. [PubMed] [Google Scholar]
  23. Gros P., Ben Neriah Y. B., Croop J. M., Housman D. E. Isolation and expression of a complementary DNA that confers multidrug resistance. Nature. 1986 Oct 23;323(6090):728–731. doi: 10.1038/323728a0. [DOI] [PubMed] [Google Scholar]
  24. Gudkov A. V., Zelnick C. R., Kazarov A. R., Thimmapaya R., Suttle D. P., Beck W. T., Roninson I. B. Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNA. Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3231–3235. doi: 10.1073/pnas.90.8.3231. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Harker W. G., Slade D. L., Drake F. H., Parr R. L. Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II beta isoform. Biochemistry. 1991 Oct 15;30(41):9953–9961. doi: 10.1021/bi00105a020. [DOI] [PubMed] [Google Scholar]
  26. Hochhauser D., Stanway C. A., Harris A. L., Hickson I. D. Cloning and characterization of the 5'-flanking region of the human topoisomerase II alpha gene. J Biol Chem. 1992 Sep 15;267(26):18961–18965. [PubMed] [Google Scholar]
  27. Jenkins J. R., Ayton P., Jones T., Davies S. L., Simmons D. L., Harris A. L., Sheer D., Hickson I. D. Isolation of cDNA clones encoding the beta isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24. Nucleic Acids Res. 1992 Nov 11;20(21):5587–5592. doi: 10.1093/nar/20.21.5587. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Keizer H. G., Schuurhuis G. J., Broxterman H. J., Lankelma J., Schoonen W. G., van Rijn J., Pinedo H. M., Joenje H. Correlation of multidrug resistance with decreased drug accumulation, altered subcellular drug distribution, and increased P-glycoprotein expression in cultured SW-1573 human lung tumor cells. Cancer Res. 1989 Jun 1;49(11):2988–2993. [PubMed] [Google Scholar]
  29. Kim R., Hirabayashi N., Nishiyama M., Saeki S., Toge T., Okada K. Expression of MDR1, GST-pi and topoisomerase II as an indicator of clinical response to adriamycin. Anticancer Res. 1991 Jan-Feb;11(1):429–431. [PubMed] [Google Scholar]
  30. Lee M. S., Wang J. C., Beran M. Two independent amsacrine-resistant human myeloid leukemia cell lines share an identical point mutation in the 170 kDa form of human topoisomerase II. J Mol Biol. 1992 Feb 20;223(4):837–843. doi: 10.1016/0022-2836(92)90245-f. [DOI] [PubMed] [Google Scholar]
  31. Marini J. C., Miller K. G., Englund P. T. Decatenation of kinetoplast DNA by topoisomerases. J Biol Chem. 1980 Jun 10;255(11):4976–4979. [PubMed] [Google Scholar]
  32. Matsuo K., Kohno K., Takano H., Sato S., Kiue A., Kuwano M. Reduction of drug accumulation and DNA topoisomerase II activity in acquired teniposide-resistant human cancer KB cell lines. Cancer Res. 1990 Sep 15;50(18):5819–5824. [PubMed] [Google Scholar]
  33. Negri C., Chiesa R., Cerino A., Bestagno M., Sala C., Zini N., Maraldi N. M., Astaldi Ricotti G. C. Monoclonal antibodies to human DNA topoisomerase I and the two isoforms of DNA topoisomerase II: 170- and 180-kDa isozymes. Exp Cell Res. 1992 Jun;200(2):452–459. doi: 10.1016/0014-4827(92)90195-e. [DOI] [PubMed] [Google Scholar]
  34. Nelson E. M., Tewey K. M., Liu L. F. Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4'-(9-acridinylamino)-methanesulfon-m-anisidide. Proc Natl Acad Sci U S A. 1984 Mar;81(5):1361–1365. doi: 10.1073/pnas.81.5.1361. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Nitiss J. L., Liu Y. X., Hsiung Y. A temperature sensitive topoisomerase II allele confers temperature dependent drug resistance on amsacrine and etoposide: a genetic system for determining the targets of topoisomerase II inhibitors. Cancer Res. 1993 Jan 1;53(1):89–93. [PubMed] [Google Scholar]
  36. Parchment R. E., Soleimanpour K., Petrose S., Murphy M. J., Jr Pharmacologic validation of human tumor clonogenic assays based on pleiotropic drug resistance: implications for individualized chemotherapy and new drug screening programs. Int J Cell Cloning. 1992 Nov;10(6):359–368. doi: 10.1002/stem.5530100608. [DOI] [PubMed] [Google Scholar]
  37. Petrov P., Drake F. H., Loranger A., Huang W., Hancock R. Localization of DNA topoisomerase II in Chinese hamster fibroblasts by confocal and electron microscopy. Exp Cell Res. 1993 Jan;204(1):73–81. doi: 10.1006/excr.1993.1010. [DOI] [PubMed] [Google Scholar]
  38. Pommier Y., Kerrigan D., Schwartz R. E., Swack J. A., McCurdy A. Altered DNA topoisomerase II activity in Chinese hamster cells resistant to topoisomerase II inhibitors. Cancer Res. 1986 Jun;46(6):3075–3081. [PubMed] [Google Scholar]
  39. Prosperi E., Sala E., Negri C., Oliani C., Supino R., Astraldi Ricotti G. B., Bottiroli G. Topoisomerase II alpha and beta in human tumor cells grown in vitro and in vivo. Anticancer Res. 1992 Nov-Dec;12(6B):2093–2099. [PubMed] [Google Scholar]
  40. Schneider E., Horton J. K., Yang C. H., Nakagawa M., Cowan K. H. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Res. 1994 Jan 1;54(1):152–158. [PubMed] [Google Scholar]
  41. Schwartz D. C., Cantor C. R. Separation of yeast chromosome-sized DNAs by pulsed field gradient gel electrophoresis. Cell. 1984 May;37(1):67–75. doi: 10.1016/0092-8674(84)90301-5. [DOI] [PubMed] [Google Scholar]
  42. Taagepera S., Rao P. N., Drake F. H., Gorbsky G. J. DNA topoisomerase II alpha is the major chromosome protein recognized by the mitotic phosphoprotein antibody MPM-2. Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8407–8411. doi: 10.1073/pnas.90.18.8407. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Takano H., Kohno K., Ono M., Uchida Y., Kuwano M. Increased phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of human cancer KB cells. Cancer Res. 1991 Aug 1;51(15):3951–3957. [PubMed] [Google Scholar]
  44. Tan K. B., Mattern M. R., Eng W. K., McCabe F. L., Johnson R. K. Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. J Natl Cancer Inst. 1989 Nov 15;81(22):1732–1735. doi: 10.1093/jnci/81.22.1732. [DOI] [PubMed] [Google Scholar]
  45. Tsai-Pflugfelder M., Liu L. F., Liu A. A., Tewey K. M., Whang-Peng J., Knutsen T., Huebner K., Croce C. M., Wang J. C. Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22. Proc Natl Acad Sci U S A. 1988 Oct;85(19):7177–7181. doi: 10.1073/pnas.85.19.7177. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Ueda K., Cornwell M. M., Gottesman M. M., Pastan I., Roninson I. B., Ling V., Riordan J. R. The mdr1 gene, responsible for multidrug-resistance, codes for P-glycoprotein. Biochem Biophys Res Commun. 1986 Dec 30;141(3):956–962. doi: 10.1016/s0006-291x(86)80136-x. [DOI] [PubMed] [Google Scholar]
  47. Uemura T., Ohkura H., Adachi Y., Morino K., Shiozaki K., Yanagida M. DNA topoisomerase II is required for condensation and separation of mitotic chromosomes in S. pombe. Cell. 1987 Sep 11;50(6):917–925. doi: 10.1016/0092-8674(87)90518-6. [DOI] [PubMed] [Google Scholar]
  48. Versantvoort C. H., Broxterman H. J., Pinedo H. M., de Vries E. G., Feller N., Kuiper C. M., Lankelma J. Energy-dependent processes involved in reduced drug accumulation in multidrug-resistant human lung cancer cell lines without P-glycoprotein expression. Cancer Res. 1992 Jan 1;52(1):17–23. [PubMed] [Google Scholar]
  49. Volm M., Mattern J. Expression of topoisomerase II, catalase, metallothionein and thymidylate-synthase in human squamous cell lung carcinomas and their correlation with doxorubicin resistance and with patients' smoking habits. Carcinogenesis. 1992 Nov;13(11):1947–1950. doi: 10.1093/carcin/13.11.1947. [DOI] [PubMed] [Google Scholar]
  50. Webb C. D., Latham M. D., Lock R. B., Sullivan D. M. Attenuated topoisomerase II content directly correlates with a low level of drug resistance in a Chinese hamster ovary cell line. Cancer Res. 1991 Dec 15;51(24):6543–6549. [PubMed] [Google Scholar]
  51. Woessner R. D., Mattern M. R., Mirabelli C. K., Johnson R. K., Drake F. H. Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ. 1991 Apr;2(4):209–214. [PubMed] [Google Scholar]
  52. Zaman G. J., Flens M. J., van Leusden M. R., de Haas M., Mülder H. S., Lankelma J., Pinedo H. M., Scheper R. J., Baas F., Broxterman H. J. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):8822–8826. doi: 10.1073/pnas.91.19.8822. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Zini N., Santi S., Ognibene A., Bavelloni A., Neri L. M., Valmori A., Mariani E., Negri C., Astaldi-Ricotti G. C., Maraldi N. M. Discrete localization of different DNA topoisomerases in HeLa and K562 cell nuclei and subnuclear fractions. Exp Cell Res. 1994 Feb;210(2):336–348. doi: 10.1006/excr.1994.1046. [DOI] [PubMed] [Google Scholar]
  54. de Jong S., Zijlstra J. G., de Vries E. G., Mulder N. H. Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res. 1990 Jan 15;50(2):304–309. [PubMed] [Google Scholar]
  55. van Loon A. A., Groenendijk R. H., Timmerman A. J., van der Schans G. P., Lohman P. H., Baan R. A. Quantitative detection of DNA damage in cells after exposure to ionizing radiation by means of an improved immunochemical assay. Mutat Res. 1992 Jun;274(1):19–27. doi: 10.1016/0921-8777(92)90040-a. [DOI] [PubMed] [Google Scholar]
  56. van der Schans G. P., van Loon A. A., Groenendijk R. H., Baan R. A. Detection of DNA damage in cells exposed to ionizing radiation by use of anti-single-stranded DNA monoclonal antibody. Int J Radiat Biol. 1989 May;55(5):747–760. doi: 10.1080/09553008914550801. [DOI] [PubMed] [Google Scholar]
  57. van der Zee A. G., de Jong S., Keith W. N., Hollema H., Boonstra H., de Vries E. G. Quantitative and qualitative aspects of topoisomerase I and II alpha and beta in untreated and platinum/cyclophosphamide treated malignant ovarian tumors. Cancer Res. 1994 Feb 1;54(3):749–755. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES